Psychiatric Hospitalization and Length of Stay Differences in Cannabis Users and Non-Users with a Primary Discharge Diagnosis of Schizophrenia or Schizoaffective Disorder

References

• Andréasson, S., Engström, A., Allebeck, P., & Rydberg, U. (1987). Cannabis and schizophrenia a longitudinal study of Swedish conscripts. The Lancet, 330(8574), 1483–1486. https://doi.org/10.1016/S0140-6736(87)92620-1
   Web of Science ®Google Scholar
• Arseneault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A., & Moffitt, T. E. (2002). Cannabis use in adolescence and risk for adult psychosis: Longitudinal prospective study. BMJ (Clinical Research Ed.), 325(7374), 1212–1213. https://doi.org/10.1136/bmj.325.7374.1212
   PubMed Web of Science ®Google Scholar
• Di Forti, M., Marconi, A., Carra, E., Fraietta, S., Trotta, A., Bonomo, M., Bianconi, F., Gardner-Sood, P., O’Connor, J., Russo, M., Stilo, S. A., Marques, T. R., Mondelli, V., Dazzan, P., Pariante, C., David, A. S., Gaughran, F., Atakan, Z., Iyegbe, C., … Murray, R. M. (2015). Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: A case-control study. The Lancet. Psychiatry, 2(3), 233–238. https://doi.org/10.1016/S2215-0366(14)00117-5
   PubMed Web of Science ®Google Scholar
• Di Forti, M., Sallis, H., Allegri, F., Trotta, A., Ferraro, L., Stilo, S. A., Marconi, A., La Cascia, C., Reis Marques, T., Pariante, C., Dazzan, P., Mondelli, V., Paparelli, A., Kolliakou, A., Prata, D., Gaughran, F., David, A. S., Morgan, C., Stahl, D., … Murray, R. M. (2014). Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophrenia Bulletin, 40(6), 1509–1517. https://doi.org/10.1093/schbul/sbt181
   PubMed Web of Science ®Google Scholar
• D’Souza, D. C., Abi-Saab, W. M., Madonick, S., Forselius-Bielen, K., Doersch, A., Braley, G., Gueorguieva, R., Cooper, T. B., & Krystal, J. H. (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. Biological Psychiatry, 57(6), 594–608. https://doi.org/10.1016/j.biopsych.2004.12.006
   PubMed Web of Science ®Google Scholar
• Hasin, D. S., Kerridge, B. T., Saha, T. D., Huang, B., Pickering, R., Smith, S. M., Jung, J., Zhang, H., & Grant, B. F. (2016). Prevalence and correlates of DSM-5 cannabis use disorder, 2012-2013: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions-III. The American Journal of Psychiatry, 173(6), 588–599. https://doi.org/10.1176/appi.ajp.2015.15070907
   PubMed Web of Science ®Google Scholar
• Galvez-Buccollini, J. A., Proal, A. C., Tomaselli, V., Trachtenberg, M., Coconcea, C., Chun, J., Manschreck, T., Fleming, J., & Delisi, L. E. (2012). Association between age at onset of psychosis and age at onset of cannabis use in non-affective psychosis. Schizophrenia Research, 139(1–3), 157–160. https://doi.org/10.1016/j.schres.2012.06.007
   PubMed Web of Science ®Google Scholar
• Iseger, T. A., & Bossong, M. G. (2015). A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophrenia Research, 162(1–3), 153–161. https://doi.org/10.1016/j.schres.2015.01.033
   PubMed Web of Science ®Google Scholar
• Karniol, I. G., Shirakawa, I., Kasinski, N., Pfeferman, A., & Carlini, E. A. (1974). Cannabidiol interferes with the effects of delta 9 - tetrahydrocannabinol in man. European Journal of Pharmacology, 28(1), 172–177. https://doi.org/10.1016/0014-2999(74)90129-0
   PubMed Web of Science ®Google Scholar
• Koskinen, J., Löhönen, J., Koponen, H., Isohanni, M., & Miettunen, J. (2010). Rate of cannabis use disorders in clinical samples of patients with schizophrenia: A meta-analysis. Schizophrenia Bulletin, 36(6), 1115–1130. https://doi.org/10.1093/schbul/sbp031
   PubMed Web of Science ®Google Scholar
• Marconi, A., Di Forti, M., Lewis, C. M., Murray, R. M., & Vassos, E. (2016). Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophrenia Bulletin, 42(5), 1262–1269. https://doi.org/10.1093/schbul/sbw003
   PubMed Web of Science ®Google Scholar
• McGuire, P., Robson, P., Cubala, W. J., Vasile, D., Morrison, P. D., Barron, R., Taylor, A., & Wright, S. (2018). Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: A multicenter randomized controlled trial. The American Journal of Psychiatry, 175(3), 225–231. https://doi.org/10.1176/appi.ajp.2017.17030325
   PubMed Web of Science ®Google Scholar
• McLoughlin, B. C., Pushpa‐Rajah, J. A., Gillies, D., Rathbone, J., Variend, H., Kalakouti, E., & Kyprianou, K. (2014). Cannabis and schizophrenia. Cochrane Database Syst. Rev, (10). https://doi.org/10.1002/14651858.CD004837.pub3
   Google Scholar
• Schubart, C. D., Sommer, I. E. C., Fusar-Poli, P., De Witte, L., Kahn, R. S., & Boks, M. P. M. (2014). Cannabidiol as a potential treatment for psychosis. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology, 24(1), 51–64.https://doi.org/10.1016/j.euroneuro.2013.11.002
   PubMed Web of Science ®Google Scholar
• Schoeler, T., Monk, A., Sami, M. B., Klamerus, E., Foglia, E., Brown, R., Camuri, G., Altamura, A. C., Murray, R., & Bhattacharyya, S. (2016). Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis. The Lancet Psychiatry, 3(3), 215–225. https://doi.org/10.1016/S2215-0366(15)00363-6
   PubMed Web of Science ®Google Scholar
• Tosato, S., Lasalvia, A., Bonetto, C., Mazzoncini, R., Cristofalo, D., De Santi, K., Bertani, M., Bissoli, S., Lazzarotto, L., Marrella, G., Lamonaca, D., Riolo, R., Gardellin, F., Urbani, A., Tansella, M., & Ruggeri, M. (2013). The impact of cannabis use on age of onset and clinical characteristics in first-episode psychotic patients. Data from the Psychosis Incident Cohort Outcome Study (PICOS). Journal of Psychiatric Research, 47(4), 438–444. https://doi.org/10.1016/j.jpsychires.2012.11.009
   PubMed Web of Science ®Google Scholar
• Williams, S. R., Agapoff, J. R., IV, Lu, B. Y., Hishinuma, E. S., & Lee, M. (2019). The frequency of hospitalizations and length of stay differences between schizophrenic and schizoaffective disorder inpatients who use cannabis. Journal of Substance Use, 24(1), 21–28. https://doi.org/10.1080/14659891.2018.1489013
   Web of Science ®Google Scholar
• Zhornitsky, S., & Potvin, S. (2012). Cannabidiol in humans-the quest for therapeutic targets. Pharmaceuticals (Basel, Switzerland), 5(5), 529–552. https://doi.org/10.3390/ph5050529
   PubMedGoogle Scholar